StockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)

StockNews.com began coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM – Get Rating) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

BLCM has been the subject of several other research reports. Zacks Investment Research downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. LADENBURG THALM/SH SH initiated coverage on shares of Bellicum Pharmaceuticals in a research note on Wednesday, February 16th. They set a “buy” rating and a $5.00 price objective for the company. Finally, TheStreet cut shares of Bellicum Pharmaceuticals from a “c-” rating to a “d-” rating in a research note on Friday, April 8th.

NASDAQ BLCM opened at $1.43 on Friday. Bellicum Pharmaceuticals has a 52-week low of $1.34 and a 52-week high of $4.04. The company has a 50-day simple moving average of $1.80 and a 200 day simple moving average of $1.73. The company has a market capitalization of $12.31 million, a PE ratio of -1.23 and a beta of 1.46.

Bellicum Pharmaceuticals (NASDAQ:BLCM – Get Rating) last posted its quarterly earnings data on Thursday, March 24th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter. The company had revenue of $0.50 million for the quarter. On average, research analysts predict that Bellicum Pharmaceuticals will post -2.23 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. Virtu Financial LLC bought a new stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Get Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 21,792 shares of the biopharmaceutical company’s stock, valued at approximately $32,000. Virtu Financial LLC owned about 0.26% of Bellicum Pharmaceuticals at the end of the most recent reporting period. 28.09% of the stock is currently owned by institutional investors.

About Bellicum Pharmaceuticals (Get Rating)

Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.

Featured Articles